New drug aims to stop Alzheimer's before it starts in gene carriers

NCT ID NCT07399171

Recruiting now Prevention Sponsor: Halia Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This study tests whether the drug HT-4253 can lower Alzheimer's risk in people aged 50-75 who carry the APOE4 gene and have high levels of amyloid in their blood. The 112 participants will receive either the drug or a placebo for 48 weeks. The main goal is to see if the drug can shift their amyloid risk score from high to low.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HT-4253
What this could lead to: If successful, this could point toward a way to lower Alzheimer's risk in people with the APOE4 gene variant.
What could go wrong: This is an early Phase 2a trial with only 112 participants, so results may not apply widely. The drug may not improve amyloid risk scores or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMERS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMERS DISEASE

Contacts and locations

Locations

Burjeel Medical City
RECRUITING

Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates
Cleveland Clinic Abu Dhabi
NOT_YET_RECRUITING

Abu Dhabi, United Arab Emirates
Sheikh Shakbout Medical City (SSMC)
NOT_YET_RECRUITING

Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates

More trials for these conditions

Other studies related to the condition(s) this trial covers.